Bayer AG Doubles Down on Indian Agri Play, Buys 11.9% Stake in Bayer CropScience for ₹2,207 Crore

Bayer AG, the Germany-headquartered global life sciences group, acquired 53,54,030 shares of listed agrochemical firm Bayer CropScience Ltd on Wednesday in a single block transaction on the National Stock Exchange (NSE), according to exchange data cited by PTI. The shares changed hands at an average price of ₹4,122.30 apiece, putting the total deal value at ₹2,207.09 crore.

The seller was fellow promoter entity Bayer CropScience Aktiengesellschaft (AG), which offloaded an equal number of shares and fully exited the Indian company. Because both buyer and seller were promoter entities, the transaction is classified as an inter-promoter transfer — meaning the combined promoter holding in Bayer CropScience remains intact and no open-offer obligation is triggered for public shareholders.

On Thursday, shares of Bayer CropScience slipped nearly 1% to trade at ₹4,128 on the NSE, a modest reaction consistent with the deal's structural rather than commercial nature.

Before Wednesday's transaction, Bayer AG held a relatively modest 8.43% direct stake in the Indian entity. The acquisition of an additional 11.91% has lifted that figure to 20.34%, effectively consolidating what was previously split between two Bayer group entities into a single, more substantial holding.

The exit of Bayer CropScience Aktiengesellschaft from the shareholder register simplifies the ownership structure, removing a layer of cross-holding that existed between the German parent and its Indian listed subsidiary. Analysts and corporate governance observers typically view such consolidation as a signal of stronger operational and financial integration between a parent and its subsidiary.

For minority shareholders, the key takeaway is continuity: overall promoter shareholding is unchanged, and the restructuring does not alter the public float or trigger any mandatory offer under SEBI's Substantial Acquisition of Shares and Takeovers Regulations.

The inter-promoter consolidation comes on the back of a robust performance year for Bayer CropScience, lending credence to the parent's decision to increase direct exposure.

Full-year FY2025-26 highlights:

• Net profit grew 21% to ₹689.2 crore, up from the previous fiscal
• Revenue climbed to ₹5,675 crore from ₹5,473 crore in FY2024-25

Q4 FY2025-26 (quarter ended March 2026):

• Net profit rose 13% to ₹162.1 crore, compared with ₹143.3 crore a year earlier
• Revenue from operations increased 5% to ₹1,100 crore from ₹1,046 crore

The consistent growth trajectory across both quarterly and full-year metrics underscores Bayer CropScience's resilience in the Indian agrochemical market, where demand for crop-protection solutions has remained firm amid evolving pest pressures and expanding farm mechanisation.

Bayer AG describes itself as a Germany-based global life sciences company with operations across pharmaceuticals, consumer health, and crop science. Its decision to consolidate promoter ownership under a single entity in India is consistent with a broader global trend of multinational agrochemical majors rationalising their subsidiary structures in high-growth emerging markets.

For India's agri-input industry, the signal is clear: a global leader is deepening its commitment to the country at a time when Indian agriculture is under pressure to improve productivity and reduce post-harvest losses. Bayer CropScience's product portfolio — spanning herbicides, fungicides, insecticides, and seed treatments — is directly relevant to the challenges facing Indian farmers across kharif and rabi seasons.

The transaction also highlights the continued attractiveness of India's listed agrochemical space to long-term strategic investors, even as near-term market sentiment kept the stock marginally in the red on Thursday.